Principal Investigator
Lynn Feun
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20221105
Clinical Trial Summary
A Phase II study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Pancreatic, Liver, and Related Cancers
Contact Information
Phone Number
305-243-2647